stoxline Quote Chart Rank Option Currency Glossary
Neoleukin Therapeutics, Inc. (NLTX)
3.49  0.05 (1.45%)    12-18 16:00
Open: 3.45
High: 3.59
Volume: 109,095
Pre. Close: 3.44
Low: 3.42
Market Cap: 8(M)
Technical analysis
2024-01-12 4:52:50 PM
Short term     
Mid term     
Targets 6-month :  12.15 1-year :  17.19
Resists First :  10.4 Second :  14.72
Pivot price 13.12
Supports First :  3.42 Second :  2.84
MAs MA(5) :  11.47 MA(20) :  13.26
MA(100) :  14.13 MA(250) :  13.82
MACD MACD :  -0.9 Signal :  -0.3
%K %D K(14,3) :  25.4 D(3) :  30.1
RSI RSI(14): 16
52-week High :  18.79 Low :  2.02
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ NLTX ] has closed below the lower bollinger band by 42.4%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ NLTX ] is to continue within current trading range. It is unclear right now based on current values. 266.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 3.59 - 3.61 3.61 - 3.62
Low: 3.38 - 3.4 3.4 - 3.41
Close: 3.46 - 3.49 3.49 - 3.52
Company Description

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.

Headline News

Thu, 14 Dec 2023
Neoleukin Therapeutics Announces 1-for-4 Reverse Stock Split - GlobeNewswire

Tue, 18 Jul 2023
Neurogene and Neoleukin Announce Definitive Merger Agreement - Yahoo Finance

Tue, 23 May 2023
Biomed Industries, Inc. Offers to acquire Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) - AccessWire

Thu, 09 Mar 2023
Neoleukin Therapeutics Seeks Strategic Alternatives, To Layoff More In Round 2 Within 6 Months - Yahoo Finance

Tue, 15 Nov 2022
Neoleukin Pauses Development Of NL-201, Cuts 40% Of Employee Strength - Yahoo Finance

Mon, 09 Aug 2021
Looking Back In On Neoleukin Therapeutics (NASDAQ:NLTX) - Seeking Alpha

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Drug Manufacturers - Specialty & Generic
Shares Out 2 (M)
Shares Float 1 (M)
Held by Insiders 0 (%)
Held by Institutions 0 (%)
Shares Short 7 (K)
Shares Short P.Month 9 (K)
Stock Financials
EPS -12.28
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 34.18
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -18.8 %
Return on Equity (ttm) -37.9 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -13.41
Qtrly Earnings Growth 0 %
Operating Cash Flow -32 (M)
Levered Free Cash Flow -20 (M)
Stock Valuations
PE Ratio -0.29
PEG Ratio 0
Price to Book value 0.1
Price to Sales 0
Price to Cash Flow -0.26
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android